Home Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease
 

Keywords :   


Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease

2015-04-23 09:30:00| Merck.com - Research & Development News

Dateline City: VIENNA C-SURFER Trial is First to Investigate an All-Oral Ribavirin-Free Hepatitis C Treatment Regimen in Treatment-Nave and Treatment-Experienced Patients with Advanced Chronic Kidney Disease Infected with Hepatitis C Virus Genotype 1 VIENNA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data from C-SURFER, the companys Phase 2/3 clinical trial evaluating the investigational once-daily treatment regimen of grazoprevir (100mg) and elbasvir (50mg) in patients with advanced chronic kidney disease (CKD) infected with chronic hepatitis C virus (HCV) genotype 1 (GT1).1 Treatment-nave patients and patients who failed prior pegylated interferon HCV therapy, with or without cirrhosis, all of whom had Language: English Contact: Media:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with results advanced study

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
14.11
14.115
14.11MTGfoil
14.11
14.11sw14000XH 8000
14.11katie
14.11EX 330 HP SAR
14.11 M1
More »